Because the p53 pathway is inactivated by deletion of mutation of p53 or by inhibitor overexpression (e.g., Mdm2 or Mdm4 overactivation), reactivating the WT p53 must be specifically designed to the genetics of a specific tumor type, depending on the method by which p53 is inhibited. Here, MDM2 is linked to neoplasm.